T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study

Francesco Schettini, Lucia Del Mastro, Marta Bonotto et al.|ESMO Open|2021

Cited by 22